Filing Details
Coya Therapeutics, Inc. (NASDAQ:COYA) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedNASDAQ:COYA
Coya Therapeutics, Inc. (COYA) Reports Material Event to SEC
Coya Therapeutics, Inc. (NASDAQ:COYA) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Coya Therapeutics, Inc. (NASDAQ:COYA) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Coya Therapeutics, Inc. filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock trades at $4.80 with a market capitalization of $104.0 million as of the filing date.
- Form 8-K filings are used to report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
Coya Therapeutics, Inc.'s stock currently trades at $4.80 with a market capitalization of $104.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Coya Therapeutics, Inc.'s stock.
All SEC filings for Coya Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View COYA Stock Page
Frequently Asked Questions
Where can I read COYA's SEC filings?
Browse all filings on our COYA SEC filings page.
What types of SEC filings does Coya Therapeutics, Inc. file?
Public companies like Coya Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.